Johnson & Johnson 's (NYSE: JNJ) Remicade is its best-selling drug, but a cheaper biosimilar to Remicade launched last year, and that's forcing J&J to cut prices to maintain its market share. Is ...

A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira ...

Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

In this clip from The Motley Fool's Industry Focus: Healthcare podcast, Kristine Harjes is joined by Todd Campbell to discuss Remicade's first-quarter sales and how the company's responding to the ...